tert-butyl N-[(1R,2S)-2-(methanesulfonyloxy)-2,3-dihydro-1H-inden-1-yl]carbamate | 403860-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: tert-butyl N-[(1R,2S)-2-(methanesulfonyloxy)-2,3-dihydro-1H-inden-1-yl]carbamate
• 英文别名: (1R,2S)-1-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-inden-2-yl methanesulfonate；(1R,2S)-1-[(1,1-dimethylethoxy)carbonylamino]-2-methanesulphonyloxyindan；(1R,2S)-cis-1-[(1,1-dimethylethoxy)carbonylamino]-2-methanesulphonyloxyindan；(1R,2s)-1-(tert-butoxycarbonylamino)-2,3-dihydro-1H-inden-2-yl methanesulfonate；[(1R,2S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1H-inden-2-yl] methanesulfonate
• CAS: 403860-49-1
• 化学式: C₁₅H₂₁NO₅S
• 分子量: 327.401
• InChiKey: CGXCOKLWNSZOMM-QWHCGFSZSA-N

物化性质

• 沸点：
  508.4±50.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(1R,2S)-2-(methanesulfonyloxy)-2,3-dihydro-1H-inden-1-yl]carbamate 在 palladium 10% on activated carbon sodium azide 、 氢气 作用下， 以 异丁酰胺 、 乙酸乙酯 为溶剂， 反应 30.0h， 以98%的产率得到(1R,2R)-1-(BOC-氨基)-2-氨基二氢茚
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY
  [FR] DERIVES D'AMIDE HETEROCYCLIQUE AYANT UNE ACTIVITE INHIBITRICE DE LA GLYCOGENE PHOSPHORYLASE

  摘要：

  一种化合物的分子式（1）或其药用可接受的盐，其中：R4和R5一起是-S-C(R6)=C(R7)-或-C(R7)=C(R6)-S-；A是苯基或杂环芳基；R1例如被选择自卤素、硝基、氰基、羟基、羧基、氨基甲酰基、N-(1-4C)烷基甲酰基、N-(1-4C)烷基磺酰基、(1-4C)烷基、(1-4C)烷氧基、(1-4C)烷酰基、(1-4C)烷酰氧基、羟基(1-4C)烷基、氟甲基和-NHSO2(1-4C)烷基；或者，当n为2时，两个R1基团与它们连接的A的碳原子一起，可以形成一个含有1或2个杂原子（独立选择自O、S和N）的4至7个成员饱和环；R2和R3与它们连接的氮一起形成一个可选地取代的4至7个成员的杂环环；具有糖原磷酸化酶抑制活性，因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态中具有价值。描述了制备化合物和含有它们的药物组合物的过程。

  公开号：

  WO2005020986A1
• 作为产物：
  描述：

  (1R,2S)-1-氨基-2-茚醇 在 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.5h， 生成 tert-butyl N-[(1R,2S)-2-(methanesulfonyloxy)-2,3-dihydro-1H-inden-1-yl]carbamate
  参考文献：
  名称：

  [EN] INDANE DERIVATIVES AS MGLUR7 MODULATORS
  [FR] DÉRIVÉS D'INDANE UTILISÉS COMME MODULATEURS DE MGLUR7

  摘要：

  本发明提供了式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4a和R4b如规范中定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。式（I）的化合物是mGluR7调节剂。

  公开号：

  WO2017131221A1

文献信息

• Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
  申请人：——

  公开号：US20030232875A1

  公开（公告）日：2003-12-18

  Heterocyclic amide derivatives, of formula (I): wherein —X-Y-Z- is selected from —S—CR 4 ═CR 5 —, —CR 4 ═CR 5 —S—, —O—CR 4 ═CR 5 —, —CR 4 ═CR 5 —O—, —N═CR 4 —S—, —S—CR 4 ═N—, —NR 6 —CR 4 ═CR 5 — and —CR 4 ═CR 5 —NR 6 —; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; (with provisos); possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  杂环酰胺衍生物的化学式（I）：其中—X-Y-Z-选择自—S—CR4═CR5—，—CR4═CR5—S—，—O—CR4═CR5—，—CR4═CR5—O—，—N═CR4—S—，—S—CR4═N—，—NR6—CR4═CR5—和—CR4═CR5—NR6—；或其药学上可接受的盐或体内可水解酯；（附带条件）；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。
• [EN] INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY<br/>[FR] DERIVES D'INDOLAMIDE POSSEDANT UNE ACTIVITE INHIBITRICE DE LA GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2005020985A1

  公开（公告）日：2005-03-10

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; wherein: A is phenylene or heteroarylene; n is 0, 1 or 2; m is 0, 1 or 2; R' is for example selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, N-(1-4C)alkylcarbamoyl, N-(1-4C)alkylsulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1­4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, and -NHSO2(1­4C)alkyl; or, when n is 2, the two R1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from 0, S and N; R2 and R3 together with the nitrogen to which they are attached form an optionally substituted 4- to 7-membered, heterocyclic ring; and R4 is for example halo or (1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  该化合物的结构式（1）或其药用盐或前药；其中：A为苯基或杂环烷基；n为0、1或2；m为0、1或2；R'例如选自卤素、硝基、氰基、羟基、羧基、氨基甲酰基、N-（1-4C）烷基甲酰基、N-（1-4C）烷基磺酰基、（1-4C）烷基、（1-4C）烷氧基、（1-4C）烷酰基、（1-4C）烷酰氧基、羟基（1-4C）烷基、氟甲基和-NHSO2（1-4C）烷基；或者，当n为2时，两个R1基团与它们连接的A的碳原子一起可以形成一个含有1或2个杂原子（独立选择自0、S和N）的4到7元饱和环；R2和R3与它们连接的氮形成一个可选择取代的4到7元杂环；R4例如为卤素或（1-4C）烷基；具有糖原磷酸化酶抑制活性，并因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备该化合物和含有它们的药物组合物的方法。
• Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
  申请人：Whittamore Robert Owen Paul

  公开号：US20050131052A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: Z is CH or nitrogen; R 4 and R 5 together are either —S—C(R 6 )═C(R 7 )— or —C(R 7 )═C(R 6 )—S—; R 6 and R 7 are selected from for example hydrogen, halo, C 1-4 alkyl, and C 1-4 alkanoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is —NR 2 R 3 or —OR 3 ; R 2 and R 3 are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 4 is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  化合物的异环酰胺式（1），其中：Z为CH或氮；R4和R5一起是—S—C（R6）═C（R7）—或—C（R7）═C（R6）—S—；R6和R7选择自例如氢，卤素，C1-4烷基和C1-4烷酰基；A为苯撑或杂芳撑；n为0，1或2；R1选择自例如卤素，硝基，氰基，羟基，羧基；r为1或2；Y为—NR2R3或—OR3；R2和R3选择自例如氢，羟基，芳基，杂环基和C1-4烷基（可选地被1或2个R8基替代）；R4选择自例如氢，卤素，硝基，氰基，羟基，C1-4烷基和C1-4烷酰基；R8选择自例如羟基，—COCOOR9，—C（O）N（R9）（R10），—NHC（O）R9，（R9）（R10）N—和—COOR9；R9和R10选择自例如氢，羟基，C1-4烷基（可选地被1或2个R13取代）；R13选择自例如羟基，卤素，三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态方面具有价值。描述了制造该异环酰胺衍生物的工艺和含有它们的制药组合物。
• Indol-2-amides as glycogen phosphorylase inhibitors
  申请人：Bennett Lile Stuart Norman

  公开号：US20060199966A1

  公开（公告）日：2006-09-07

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example, R 4 is halo or (1-4C)alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; m is 0, 1 or 2; R 1 is halo, cyano or carboxy; R 2 is for example methyl; R 3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  公式（1）的化合物或其药学上可接受的盐或前药；（1）其中，例如，R4是卤素或（1-4C）烷基；A是苯基或杂环芳基；n为0、1或2；m为0、1或2；R1为卤素、氰基或羧基；R2例如为甲基；R3例如从卤（1-4C）烷基、二卤（1-4C）烷基、三氟甲基、羟基（1-4C）烷基、二羟基（2-4C）烷基、三羟基（3-4C）烷基、氰基（1-4C）烷基（在烷基上可选地用羟基取代）、（1-4C）烷氧基（1-4C）烷基、（1-4C）烷氧基（1-4C）烷氧基（1-4C）烷基、二[(1-4C）烷氧基]（1-4C）烷基、（羟基）[(1-4C）烷氧基]（1-4C）烷基；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态方面具有价值。描述了制造化合物和含有它们的制药组合物的过程。
• Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity
  申请人：Birch Alan Martin

  公开号：US20090124682A1

  公开（公告）日：2009-05-14

  A compound of the formula (1) or a pharmaceutically-acceptable salt: (A chemical formula should be inserted here—please see paper copy enclosed herewith) (1) possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  化合物的化学式（1）或其药学上可接受的盐：（化学式请参见随附的纸质副本）（1）具有糖原磷酸化酶抑制活性，因此对于治疗与糖原磷酸化酶活性增加相关的疾病状态具有价值。本文描述了制备化合物和含有它们的制药组合物的过程。